Nandini Dhiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nandini Dhiman has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Subha Narayan Rath
Regenerative Medicine and Stem Cell Laboratory (RMS), Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Kandi, Telangana 502284, India
4 shared publications - Chandra Shekhar Sharma
Indian Institute of Technology Hyderabad
2 shared publications Huseyin Sumer
Department of Chemistry and Biotechnology, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, Australia
2 shared publicationsNadin Shagaghi
Department of Chemistry and Biotechnology, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, Australia
2 shared publications- Peter Kingshott
Swinburne University of Technology
2 shared publications Akshay Joshi
Department of Biomedical Engineering, Indian Institute of Technology, Hyderabad, Telangana502285, India
1 shared publication
Latest Publications
- 31 March 2021
- Published by Taylor & Francis in Journal of 3D Printing in Medicine
- Vol. 5 (1) , 23-36
3D Bioprinting of Mesenchymal Stem Cells and Endothelial Cells in an Alginate-Gelatin-Based Bioink
Aim: Bioink is one of the essential factors in 3D bioprinting that determines the fate of cells, in our case, umbilical cord-derived mesenchymal stem cells (UMSC). The aim was to determine if the p... Graphical abstract
- 31 March 2021
- Published by Taylor & Francis in Journal of 3D Printing in Medicine
- Vol. 5 (1) , 23-36
3D Bioprinting of Mesenchymal Stem Cells and Endothelial Cells in an Alginate-Gelatin-Based Bioink
Aim: Bioink is one of the essential factors in 3D bioprinting that determines the fate of cells, in our case, umbilical cord-derived mesenchymal stem cells (UMSC). The aim was to determine if the p... Graphical abstract
- 1 January 2021
- Published by Elsevier in Cytotherapy
- Vol. 23 (1) , 25-36
Indirect co-culture of lung carcinoma cells with hyperthermia-treated mesenchymal stem cells influences tumor spheroid growth in a collagen-based 3-dimensional microfluidic model
- 1 January 2021
- Published by Elsevier in Cytotherapy
- Vol. 23 (1) , 25-36
Indirect co-culture of lung carcinoma cells with hyperthermia-treated mesenchymal stem cells influences tumor spheroid growth in a collagen-based 3-dimensional microfluidic model
- 19 February 2020
- Published by Wiley in Advanced Biosystems
- Vol. 4 (4) , e1900285
Selective Cytotoxicity of a Novel Trp‐Rich Peptide against Lung Tumor Spheroids Encapsulated inside a 3D Microfluidic Device
There is a globally rising healthcare need to develop new anticancer therapies as well as to test them on biologically relevant in vitro cancer models instead of overly simplistic 2D models. To address both these needs, a 3D lung cancer spheroid model is developed using human A549 cells trapped inside a collagen gel in a compartmentalized microfluidic device and homogenously sized (35–45 µm) multicellular tumor spheroids are obtained in 5 days. The novel tryptophan‐rich peptide P1, identified earlier as a potential anticancer peptide (ACP), shows enhanced cytotoxic efficacy against A549 tumor spheroids (>75%) in clinically relevant low concentrations, while it does not affect human amniotic membrane mesenchymal stem cells at the same concentrations (<15%). The peptide also inhibits the formation of tumor spheroids by reducing cell viability as well as lowering the proliferative capacity, which is confirmed by the expression of cell proliferation marker Ki‐67. The ACP offers a novel therapeutic strategy against lung cancer cells without affecting healthy cells. The microfluidic device used is likely to be useful in helping develop models for several other cancer types to test new anticancer agents.
- 19 February 2020
- Published by Wiley in Advanced Biosystems
- Vol. 4 (4) , e1900285
Selective Cytotoxicity of a Novel Trp‐Rich Peptide against Lung Tumor Spheroids Encapsulated inside a 3D Microfluidic Device
There is a globally rising healthcare need to develop new anticancer therapies as well as to test them on biologically relevant in vitro cancer models instead of overly simplistic 2D models. To address both these needs, a 3D lung cancer spheroid model is developed using human A549 cells trapped inside a collagen gel in a compartmentalized microfluidic device and homogenously sized (35–45 µm) multicellular tumor spheroids are obtained in 5 days. The novel tryptophan‐rich peptide P1, identified earlier as a potential anticancer peptide (ACP), shows enhanced cytotoxic efficacy against A549 tumor spheroids (>75%) in clinically relevant low concentrations, while it does not affect human amniotic membrane mesenchymal stem cells at the same concentrations (<15%). The peptide also inhibits the formation of tumor spheroids by reducing cell viability as well as lowering the proliferative capacity, which is confirmed by the expression of cell proliferation marker Ki‐67. The ACP offers a novel therapeutic strategy against lung cancer cells without affecting healthy cells. The microfluidic device used is likely to be useful in helping develop models for several other cancer types to test new anticancer agents.
- 1 January 2020
- Published by Elsevier
- p. 379-398
Perfusion-based 3D tumor-on-chip devices for anticancer drug testing
- 1 January 2020
- Published by Elsevier
- p. 379-398
Perfusion-based 3D tumor-on-chip devices for anticancer drug testing
- Open Access
- 26 July 2019
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 14 (7) , 647-661
Isogenic-Induced Endothelial Cells Enhance Osteogenic Differentiation of Mesenchymal Stem Cells on Silk Fibroin Scaffold
Aim: We investigated the role of induced endothelial cells (iECs) in mesenchymal stem cells (MSCs)/iECs co-culture and assessed their osteogenic ability on silk fibroin nanofiber scaffolds. Methods: The osteogenic differentiation was assessed by the ALP assay, calcium assay and gene expression studies. Results: The osteogenic differentiation of the iECs co-cultures was found to be higher than the MSCs group and proximal to endothelial cells (ECs) co-cultures. Furthermore, the usage of isogenic iECs for co-culture increased the osteogenic and endothelial gene expression. Conclusion: These findings suggest that iECs mimic endothelial cells when co-cultured with MSCs and that one MSCs source can be used to give rise to both MSCs and iECs. The isogenic MSCs/iECs co-culture provides a new option for bone tissue engineering applications.
- 26 July 2019
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 14 (7) , 647-661
Open AccessIsogenic-Induced Endothelial Cells Enhance Osteogenic Differentiation of Mesenchymal Stem Cells on Silk Fibroin Scaffold
Aim: We investigated the role of induced endothelial cells (iECs) in mesenchymal stem cells (MSCs)/iECs co-culture and assessed their osteogenic ability on silk fibroin nanofiber scaffolds. Methods: The osteogenic differentiation was assessed by the ALP assay, calcium assay and gene expression studies. Results: The osteogenic differentiation of the iECs co-cultures was found to be higher than the MSCs group and proximal to endothelial cells (ECs) co-cultures. Furthermore, the usage of isogenic iECs for co-culture increased the osteogenic and endothelial gene expression. Conclusion: These findings suggest that iECs mimic endothelial cells when co-cultured with MSCs and that one MSCs source can be used to give rise to both MSCs and iECs. The isogenic MSCs/iECs co-culture provides a new option for bone tissue engineering applications.
- 1 July 2019
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 137, 236-254
On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy
- 1 July 2019
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 137, 236-254
On-chip anticancer drug screening – Recent progress in microfluidic platforms to address challenges in chemotherapy
- 1 June 2017
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 2, 22-28
Three-dimensional bioprinting for bone tissue regeneration
- 1 June 2017
- Published by Elsevier in Current Opinion in Biomedical Engineering
- Vol. 2, 22-28
Three-dimensional bioprinting for bone tissue regeneration